Trial Profile
GERMAN TARCEVA NON-INTERVENTIONAL STUDY in 1st Line Treatment of NSCLC EGFR Mutation Positive Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms GERTAC
- Sponsors Roche
- 01 Aug 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 May 2013 Planned End Date changed from 1 Mar 2016 to 1 Jan 2016 as reported by ClinicalTrials.gov.
- 15 Apr 2013 Planned End Date changed from 1 Jul 2016 to 1 Mar 2016 as reported by ClinicalTrials.gov.